Close Menu


The data, Tekmira President and CEO Mark Murray said in a statement, "are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting," and support the utility of RNAi in infectious diseases.

The new data in pulmonary injury and emphysema provide "support for additional clinical applications of this drug, such as treatment of acute and chronic lung injury," according to a company official.

IP Update: May 20, 2010


USPTO Publishes Three Patents, Six Patent Applications Related to RNAi

Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets."

Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.

The deal, which is independent of another arrangement under which Silence is developing siRNA drugs against AstraZeneca-specified targets, has been extended for one year.

According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.

However, the company will most likely require an additional infusion of capital before it can move any of its programs into the clinic, Traversa President and CEO Hans Petersen said.

Under the expanded deal, Silence will demonstrate functional delivery of siRNAs against new targets selected by Dainippon.

The data, which appeared in the online edition of Nature, "demonstrate that RNAi can occur in a human from a systemically delivered siRNA, and that siRNA can be used as a gene-specific therapeutic," the investigators wrote.


Researchers have sequenced the genome of the depth-dwelling giant squid.

Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.


Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.

In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.